ECP
PRTK

Empyrean Capital Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Empyrean Capital Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-669,000
Closed -$12M – 76
2017
Q4 		$12M Hold
669,000
– – 0.54% 37
2017
Q3 		$16.8M Buy
+669,000
New +$15.6M 0.65% 32

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Empyrean Capital Partners's PRTK Position: Q1 2018 in Review

Empyrean Capital Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2018, closing a stake of 669,000 shares — an estimated $12M sold.

Empyrean Capital Partners first reported a position in PRTK in Q3 2017 and held it in 2 quarters. The position peaked at $16.8M in Q3 2017. 114 funds tracked by Wall St. Rank hold PRTK as of Q1 2018.

  • Empyrean Capital Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Empyrean Capital Partners sold 669,000 Paratek Pharmaceuticals, Inc. shares in Q1 2018, an estimated $12M.
  • Empyrean Capital Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Empyrean Capital Partners's Paratek Pharmaceuticals, Inc. position peaked at $16.8M in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2018.

Based on Empyrean Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.